Literature DB >> 29847362

Safety of moderate-to-deep sedation performed by sedation practitioners: A national prospective observational study.

Lena Koers1, Suzanne Eberl, Anne Cappon, Arthur Bouwman, Wolfgang Schlack, Jeroen Hermanides, Benedikt Preckel.   

Abstract

BACKGROUND: In the Netherlands, a significant proportion of moderate-to-deep sedation is performed by sedation practitioners under the indirect supervision of an anaesthesiologist but there are limited safety data available.
OBJECTIVE: To estimate the rate of sedation-related adverse events and patient relevant outcomes (PRO).
DESIGN: This was a prospective national observational study. Data were collected with a modified adverse event reporting tool from the International Sedation Task Force of the World Society of Intravenous Anaesthesia.
SETTING: A total of 24 hospitals in the Netherlands where moderate-to-deep sedation was performed by sedation practitioners from the 1 February 2015 to 1 March 2016. PATIENTS: Consecutive adults undergoing moderate-to-deep sedation for gastrointestinal, pulmonary and cardiac procedures. INTERVENTION: Observation: Analysis included descriptive statistics and a multivariate logistic regression model for an association between adverse events and PRO. MAIN OUTCOME MEASURES: The primary outcome was the rate of unfavourable PRO (admission to ICU, permanent neurological deficit, pulmonary aspiration or death). Secondary outcome was the rate of moderate-to-good PRO (unplanned hospital admission or escalation of care). Composite outcome was the sum of all primary and secondary outcomes.
RESULTS: A total of 11 869 patients with a median age of 64 years [interquartile range 51 to 72] were included. ASA physical score distribution was: first, 19.1%; second, 57.6%; third, 21.6%; fourth, 1.2%. Minimal adverse events occurred in 1517 (12.8%), minor adverse events in 113 (1.0%) and major adverse events in 80 instances (0.7%). PRIMARY OUTCOME: Five (0.04%) unfavourable PRO were observed; four patients needing admission to the intensive care unit; and one died. Secondary outcome: 12 (0.1%) moderate-to-good PRO were observed. Moderate and major adverse events were associated with the composite outcome [3.7 (95% confidence interval 1.1 to 11.9) and 40.6 (95% confidence interval 11.0 to 150.4)], but not minimal or minor adverse events.
CONCLUSION: Moderate-to-deep sedation performed by trained sedation practitioners has a very low rate of unfavourable outcome.

Entities:  

Mesh:

Year:  2018        PMID: 29847362     DOI: 10.1097/EJA.0000000000000835

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  4 in total

1.  Patient satisfaction with deep versus light/moderate sedation for non-surgical procedures: A systematic review and meta-analysis.

Authors:  Hiroshi Hoshijima; Hitoshi Higuchi; Aiji Sato Boku; Makiko Shibuya; Yoshinari Morimoto; Toshiaki Fujisawa; Kentaro Mizuta
Journal:  Medicine (Baltimore)       Date:  2021-09-10       Impact factor: 1.817

2.  High-flow nasal cannula versus standard low-flow nasal cannula during deep sedation in patients undergoing radiofrequency atrial fibrillation catheter ablation: a single-centre randomised controlled trial.

Authors:  Marloes C Homberg; Esther A Bouman; Dominik Linz; Sander M J van Kuijk; Bert A Joosten; Wolfgang F Buhre
Journal:  Trials       Date:  2022-05-09       Impact factor: 2.728

3.  Results from the Adverse Event Sedation Reporting Tool: A Global Anthology of 7952 Records Derived from >160,000 Procedural Sedation Encounters.

Authors:  Keira P Mason; Mark G Roback; David Chrisp; Nicole Sturzenbaum; Lee Freeman; David Gozal; Firoz Vellani; David Cavanaugh; Steven M Green
Journal:  J Clin Med       Date:  2019-12-01       Impact factor: 4.241

4.  Hypoxemia during procedural sedation in adult patients: a retrospective observational study.

Authors:  Eva P C van Schaik; Paul Blankman; Wilton A Van Klei; Hans J T A Knape; Paul H H B Vaessen; Sue A Braithwaite; Leo van Wolfswinkel; Willem-Jan M Schellekens
Journal:  Can J Anaesth       Date:  2021-04-20       Impact factor: 5.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.